Bcg
- PDF / 169,429 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 41 Downloads / 182 Views
1
S
Epididymitis: case report In a retrospective, monocentric, non-randomised study of 200 patients older than 80 years, who had been newly diagnosed with high risk non muscle invasive bladder cancer (HG-NMIBC), one patient was described [age and sex not stated], who developed grade 3 epididymitis during treatment with BCG. The patient, who was enrolled in group 1 of the study, was planned to receive six biweekly intravesical BCG instillations. As epididymitis was attributed to BCG, patient’s BCG treatment was discontinued [duration of treatment to reaction onset and outcome not stated]. Author comment: "Patients in group one received six biweekly (i.e. every two weeks) intravesical BCG instillations". "The overall complication rate in group 1 was 15% (15 patients). We reported Grade 3 complications in 5 patients requiring the discontinuation of therapy: 2 had severe prostatitis, 1 had epididymitis". Racioppi M, et al. The challenges of Bacillus of Calmette-Guerin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patients. Journal of Geriatric Oncology 9: 507-512, No. 5, Sep 2018. Available from: URL: 803437366 http://doi.org/10.1016/j.jgo.2018.03.020 - Italy
0114-9954/19/1781-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 30 Nov 2019 No. 1781
